A citation-based method for searching scientific literature

Huy Gia Vuong, Ahmed M A Altibi, Uyen N P Duong, Lewis Hassell. Clin Endocrinol (Oxf) 2017
Times Cited: 50







List of co-cited articles
395 articles co-cited >1



Times Cited
  Times     Co-cited
Similarity


2015 American Thyroid Association Management Guidelines for Adult Patients with Thyroid Nodules and Differentiated Thyroid Cancer: The American Thyroid Association Guidelines Task Force on Thyroid Nodules and Differentiated Thyroid Cancer.
Bryan R Haugen, Erik K Alexander, Keith C Bible, Gerard M Doherty, Susan J Mandel, Yuri E Nikiforov, Furio Pacini, Gregory W Randolph, Anna M Sawka, Martin Schlumberger,[...]. Thyroid 2016
62

Effects of Coexistent BRAFV600E and TERT Promoter Mutations on Poor Clinical Outcomes in Papillary Thyroid Cancer: A Meta-Analysis.
Shinje Moon, Young Shin Song, Ye An Kim, Jung Ah Lim, Sun Wook Cho, Jae Hoon Moon, Seokyung Hahn, Do Joon Park, Young Joo Park. Thyroid 2017
68
30

Association between BRAF V600E mutation and mortality in patients with papillary thyroid cancer.
Mingzhao Xing, Ali S Alzahrani, Kathryn A Carson, David Viola, Rossella Elisei, Bela Bendlova, Linwah Yip, Caterina Mian, Federica Vianello, R Michael Tuttle,[...]. JAMA 2013
549
28


BRAF V600E and TERT promoter mutations cooperatively identify the most aggressive papillary thyroid cancer with highest recurrence.
Mingzhao Xing, Rengyun Liu, Xiaoli Liu, Avaniyapuram Kannan Murugan, Guangwu Zhu, Martha A Zeiger, Sara Pai, Justin Bishop. J Clin Oncol 2014
390
26

Highly prevalent TERT promoter mutations in aggressive thyroid cancers.
Xiaoli Liu, Justin Bishop, Yuan Shan, Sara Pai, Dingxie Liu, Avaniyapuram Kannan Murugan, Hui Sun, Adel K El-Naggar, Mingzhao Xing. Endocr Relat Cancer 2013
370
26


A meta-analysis of prognostic roles of molecular markers in papillary thyroid carcinoma.
Huy Gia Vuong, Uyen N P Duong, Ahmed M A Altibi, Hanh T T Ngo, Thong Quang Pham, Hung Minh Tran, Greta Gandolfi, Lewis Hassell. Endocr Connect 2017
37
29

TERT promoter mutations are a major indicator of poor outcome in differentiated thyroid carcinomas.
Miguel Melo, Adriana Gaspar da Rocha, João Vinagre, Rui Batista, Joana Peixoto, Catarina Tavares, Ricardo Celestino, Ana Almeida, Catarina Salgado, Catarina Eloy,[...]. J Clin Endocrinol Metab 2014
313
22

Association between BRAF V600E mutation and recurrence of papillary thyroid cancer.
Mingzhao Xing, Ali S Alzahrani, Kathryn A Carson, Young Kee Shong, Tae Yong Kim, David Viola, Rossella Elisei, Bela Bendlová, Linwah Yip, Caterina Mian,[...]. J Clin Oncol 2015
300
22

TERT promoter mutations and their association with BRAF V600E mutation and aggressive clinicopathological characteristics of thyroid cancer.
Xiaoli Liu, Shen Qu, Rengyun Liu, Chunjun Sheng, Xiaoguang Shi, Guangwu Zhu, Avaniyapuram Kannan Murugan, Haixia Guan, Hongyu Yu, Yangang Wang,[...]. J Clin Endocrinol Metab 2014
183
20

Revised American Thyroid Association management guidelines for patients with thyroid nodules and differentiated thyroid cancer.
David S Cooper, Gerard M Doherty, Bryan R Haugen, Richard T Kloos, Stephanie L Lee, Susan J Mandel, Ernest L Mazzaferri, Bryan McIver, Furio Pacini, Martin Schlumberger,[...]. Thyroid 2009
20

TERT promoter mutations in thyroid cancer.
Rengyun Liu, Mingzhao Xing. Endocr Relat Cancer 2016
183
20

Frequency of TERT promoter mutations in human cancers.
João Vinagre, Ana Almeida, Helena Pópulo, Rui Batista, Joana Lyra, Vasco Pinto, Ricardo Coelho, Ricardo Celestino, Hugo Prazeres, Luis Lima,[...]. Nat Commun 2013
535
16

BRAF mutation in papillary thyroid cancer and its value in tailoring initial treatment: a systematic review and meta-analysis.
Ralph P Tufano, Gilberto V Teixeira, Justin Bishop, Kathryn A Carson, Mingzhao Xing. Medicine (Baltimore) 2012
201
16

BRAF and TERT promoter mutations in the aggressiveness of papillary thyroid carcinoma: a study of 653 patients.
Langping Jin, Endong Chen, Siyang Dong, Yefeng Cai, Xiangjian Zhang, Yili Zhou, Ruichao Zeng, Fan Yang, Chuanmeng Pan, Yehuan Liu,[...]. Oncotarget 2016
76
16

TERT promoter mutations in familial and sporadic melanoma.
Susanne Horn, Adina Figl, P Sivaramakrishna Rachakonda, Christine Fischer, Antje Sucker, Andreas Gast, Stephanie Kadel, Iris Moll, Eduardo Nagore, Kari Hemminki,[...]. Science 2013
16

Current thyroid cancer trends in the United States.
Louise Davies, H Gilbert Welch. JAMA Otolaryngol Head Neck Surg 2014
898
16

TERT promoter mutations are associated with distant metastases in papillary thyroid carcinoma.
Greta Gandolfi, Moira Ragazzi, Andrea Frasoldati, Simonetta Piana, Alessia Ciarrocchi, Valentina Sancisi. Eur J Endocrinol 2015
79
16


Nomenclature Revision for Encapsulated Follicular Variant of Papillary Thyroid Carcinoma: A Paradigm Shift to Reduce Overtreatment of Indolent Tumors.
Yuri E Nikiforov, Raja R Seethala, Giovanni Tallini, Zubair W Baloch, Fulvio Basolo, Lester D R Thompson, Justine A Barletta, Bruce M Wenig, Abir Al Ghuzlan, Kennichi Kakudo,[...]. JAMA Oncol 2016
752
16

TERT, BRAF, and NRAS in Primary Thyroid Cancer and Metastatic Disease.
Miguel Melo, Adriana Gaspar da Rocha, Rui Batista, João Vinagre, Maria João Martins, Gracinda Costa, Cristina Ribeiro, Francisco Carrilho, Valeriano Leite, Cláudia Lobo,[...]. J Clin Endocrinol Metab 2017
66
16


Prognostic effects of TERT promoter mutations are enhanced by coexistence with BRAF or RAS mutations and strengthen the risk prediction by the ATA or TNM staging system in differentiated thyroid cancer patients.
Young Shin Song, Jung Ah Lim, Hoonsung Choi, Jae-Kyung Won, Jae Hoon Moon, Sun Wook Cho, Kyu Eun Lee, Young Joo Park, Ka Hee Yi, Do Joon Park,[...]. Cancer 2016
91
14

In Japanese patients with papillary thyroid carcinoma, TERT promoter mutation is associated with poor prognosis, in contrast to BRAF V600E mutation.
Almira Nasirden, Tsuyoshi Saito, Yuki Fukumura, Kieko Hara, Keisuke Akaike, Aiko Kurisaki-Arakawa, Miki Asahina, Atsushi Yamashita, Ran Tomomasa, Takuo Hayashi,[...]. Virchows Arch 2016
27
25

BRAF mutation predicts a poorer clinical prognosis for papillary thyroid cancer.
Mingzhao Xing, William H Westra, Ralph P Tufano, Yoram Cohen, Eli Rosenbaum, Kerry J Rhoden, Kathryn A Carson, Vasily Vasko, Alexandr Larin, Giovanni Tallini,[...]. J Clin Endocrinol Metab 2005
696
14

Genomic and transcriptomic hallmarks of poorly differentiated and anaplastic thyroid cancers.
Iñigo Landa, Tihana Ibrahimpasic, Laura Boucai, Rileen Sinha, Jeffrey A Knauf, Ronak H Shah, Snjezana Dogan, Julio C Ricarte-Filho, Gnana P Krishnamoorthy, Bin Xu,[...]. J Clin Invest 2016
478
14

The association of the BRAF(V600E) mutation with prognostic factors and poor clinical outcome in papillary thyroid cancer: a meta-analysis.
Tae Hyuk Kim, Young Joo Park, Jung Ah Lim, Hwa Young Ahn, Eun Kyung Lee, You Jin Lee, Kyung Won Kim, Seo Kyung Hahn, Yeo Kyu Youn, Kwang Hyun Kim,[...]. Cancer 2012
291
14

Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries.
Freddie Bray, Jacques Ferlay, Isabelle Soerjomataram, Rebecca L Siegel, Lindsey A Torre, Ahmedin Jemal. CA Cancer J Clin 2018
14

Worldwide increasing incidence of thyroid cancer: update on epidemiology and risk factors.
Gabriella Pellegriti, Francesco Frasca, Concetto Regalbuto, Sebastiano Squatrito, Riccardo Vigneri. J Cancer Epidemiol 2013
671
12

BRAF mutation in papillary thyroid carcinoma in a Japanese population: its lack of correlation with high-risk clinicopathological features and disease-free survival of patients.
Yasuhiro Ito, Hiroshi Yoshida, Rie Maruo, Shinji Morita, Toru Takano, Mitsuyoshi Hirokawa, Tomonori Yabuta, Mitsuhiro Fukushima, Hiroyuki Inoue, Chisato Tomoda,[...]. Endocr J 2009
187
12

BRAF mutation in thyroid cancer.
M Xing. Endocr Relat Cancer 2005
906
12

Dynamic Risk Stratification in Patients with Differentiated Thyroid Cancer Treated Without Radioactive Iodine.
Denise P Momesso, Fernanda Vaisman, Samantha P Yang, Daniel A Bulzico, Rossana Corbo, Mario Vaisman, R Michael Tuttle. J Clin Endocrinol Metab 2016
111
12

Delayed risk stratification, to include the response to initial treatment (surgery and radioiodine ablation), has better outcome predictivity in differentiated thyroid cancer patients.
Maria Grazia Castagna, Fabio Maino, Claudia Cipri, Valentina Belardini, Alexandra Theodoropoulou, Gabriele Cevenini, Furio Pacini. Eur J Endocrinol 2011
164
12

Regulation of mutant TERT by BRAF V600E/MAP kinase pathway through FOS/GABP in human cancer.
Rengyun Liu, Tao Zhang, Guangwu Zhu, Mingzhao Xing. Nat Commun 2018
83
12

Biologic and Clinical Perspectives on Thyroid Cancer.
James A Fagin, Samuel A Wells. N Engl J Med 2016
327
12

Highly recurrent TERT promoter mutations in human melanoma.
Franklin W Huang, Eran Hodis, Mary Jue Xu, Gregory V Kryukov, Lynda Chin, Levi A Garraway. Science 2013
12

Association of TERT Promoter Mutation, But Not BRAF Mutation, With Increased Mortality in PTC.
Jonathan R George, Ying C Henderson, Michelle D Williams, Dianna B Roberts, Hu Hei, Stephen Y Lai, Gary L Clayman. J Clin Endocrinol Metab 2015
45
11

The age- and shorter telomere-dependent TERT promoter mutation in follicular thyroid cell-derived carcinomas.
T Liu, N Wang, J Cao, A Sofiadis, A Dinets, J Zedenius, C Larsson, D Xu. Oncogene 2014
160
10

Prognostic Significance of TERT Promoter Mutations in Papillary Thyroid Carcinomas in a BRAF(V600E) Mutation-Prevalent Population.
Seung Eun Lee, Tae Sook Hwang, Yoon-La Choi, Hye Seung Han, Wan Seop Kim, Min Hye Jang, Suk Kyeong Kim, Jung Hyun Yang. Thyroid 2016
42
11


Progress in molecular-based management of differentiated thyroid cancer.
Mingzhao Xing, Bryan R Haugen, Martin Schlumberger. Lancet 2013
329
10

Genetic Analysis of 779 Advanced Differentiated and Anaplastic Thyroid Cancers.
Nikita Pozdeyev, Laurie M Gay, Ethan S Sokol, Ryan Hartmaier, Kelsi E Deaver, Stephanie Davis, Jena D French, Pierre Vanden Borre, Daniel V LaBarbera, Aik-Choon Tan,[...]. Clin Cancer Res 2018
164
10

The BRAF mutation is not associated with poor prognostic factors in Korean patients with conventional papillary thyroid microcarcinoma.
Tae Yong Kim, Won Bae Kim, Ja Young Song, Yoon Soo Rhee, Gyungyub Gong, Yong Mee Cho, Sang Yoon Kim, Seong Chul Kim, Suck Joon Hong, Young Kee Shong. Clin Endocrinol (Oxf) 2005
181
10

Concomitant RAS, RET/PTC, or BRAF mutations in advanced stage of papillary thyroid carcinoma.
Minjing Zou, Essa Y Baitei, Ali S Alzahrani, Faisal S BinHumaid, Dania Alkhafaji, Roua A Al-Rijjal, Brian F Meyer, Yufei Shi. Thyroid 2014
57
10

Hallmarks of cancer: the next generation.
Douglas Hanahan, Robert A Weinberg. Cell 2011
10


TERT promoter mutations and long-term survival in patients with thyroid cancer.
Tae Hyuk Kim, Young-Eun Kim, Soomin Ahn, Ji-Youn Kim, Chang-Seok Ki, Young Lyun Oh, Kyunga Kim, Jae Won Yun, Woong-Yang Park, Jun-Ho Choe,[...]. Endocr Relat Cancer 2016
47
10

TERT Promoter Mutation Predicts Radioiodine-Refractory Character in Distant Metastatic Differentiated Thyroid Cancer.
Xue Yang, Jiao Li, Xiaoyi Li, Zhiyong Liang, Wen Gao, Jun Liang, Shujun Cheng, Yansong Lin. J Nucl Med 2017
43
11

Worldwide Thyroid-Cancer Epidemic? The Increasing Impact of Overdiagnosis.
Salvatore Vaccarella, Silvia Franceschi, Freddie Bray, Christopher P Wild, Martyn Plummer, Luigino Dal Maso. N Engl J Med 2016
462
10


Co-cited is the co-citation frequency, indicating how many articles cite the article together with the query article. Similarity is the co-citation as percentage of the times cited of the query article or the article in the search results, whichever is the lowest. These numbers are calculated for the last 100 citations when articles are cited more than 100 times.